Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Investigator
- Diana Barb
- Ages
- 18 Years - 99 Years
- Sexes
- All
Clinical trials
-
MARITIME-SWITCH
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.